Abstract: This disclosure provides a robust, sensitive, and specific assay for the detection and measurement of DPP-4 levels in samples obtained from human patients. The disclosure further provides novel anti-DPP-4 monoclonal antibodies that recognize human DPP-4, and assay kits comprising one or more of these antibodies.
Abstract: Provided is a testing device including a flow path in which an analyte is flowed, wherein a composition containing a reagent reactive with the analyte and a lyophilic resin is placed at one position or a plurality of positions of the flow path.
Abstract: Rheumatoid arthritis is efficiently diagnosed with improved patient's convenience using a rheumatoid arthritis diagnosis composition and a kit, each including cyclic citrullinated peptide (CCP), a rheumatoid arthritis diagnosis method using the CCP, the rheumatoid arthritis diagnosis composition, or the kit, a method of obtaining information for rheumatoid arthritis diagnosis, and a method of screening a novel diagnostic marker for rheumatoid arthritis.
Type:
Grant
Filed:
September 10, 2015
Date of Patent:
April 23, 2019
Assignee:
Korea Institute of Science and Technology
Inventors:
Min Park, Min-Jung Kang, Byung Hwa Jung, Young Sook Yoo
Abstract: Described herein are methods for evaluating the risk of preterm birth in pregnant subjects. The methods involve detecting and quantifying one or more biomarkers associated with preterm birth in a biological sample from the subject. Also described herein are isolated biomarkers and kits useful in predicting the risk of preterm birth.
Type:
Grant
Filed:
July 17, 2008
Date of Patent:
April 2, 2019
Assignees:
BRIGHAM YOUNG UNIVERSITY, UNIVERSITY OF UTAH RESEARCH FOUNDATION, IHC HEALTH SERVICES
Inventors:
Steven William Graves, Michael Sean Esplin, Craig Dan Thulin
Abstract: Disclosed are: a kit and a method for diagnosing or monitoring a liver disease, comprising a detection reagent for one or more markers of cytosolic aspartate aminotransferase (cAST) and mitochondrial aspartate aminotransferase (mAST) as biomarkers in a biological sample; and an antibody used for the detection. Compared to the conventional enzyme activity measurement method, the method according to the present application can more accurately measure diagnosis or prognosis of a liver disease with high sensitivity through measurement of the amount of mAST or cAST present in the biological sample, in particular, in a blood sample.
Type:
Grant
Filed:
September 11, 2014
Date of Patent:
March 12, 2019
Assignee:
BODITECH MED INC.
Inventors:
Hong Tao Wang, Sang Yeol Park, Hyun Jeong Kim, Won Hee Lee
Abstract: There is provided a method of detecting an analyte in a sample. The method is based on colorimetry and also on the binding affinity between the analyte and a chemical substrate which may be a recognition receptor thereof. The method involves a support and a colored carrier. A kit for use in the detection is also provided.
Abstract: The present invention provides citrullinated 14-3-3? peptides and antibodies thereto and methods of using same to evaluate arthritic conditions such as rheumatoid arthritis.
Abstract: An assay method for the detection of potential for CVD or propensity to CVD in a human or non-human animal subject, said method comprising assessing the concentration of calprotectin in a calprotectin-containing sample taken from said subject.
Abstract: A method for determining an analyte in a sample suspected of containing the analyte comprises providing in combination a medium, the sample, and two or more different receptors. Each different receptor binds to at least two different epitopic sites. One of the epitopic sites is a common binding site and one of the epitopic sites is non-common binding site. The non-common epitopic sites are different for each different receptor. The receptors exhibit mono-molecular binding. The medium is incubated under conditions for binding of the receptors to the epitopic sites. The medium is examined for the presence and/or amount of complexes comprising the epitopic sites and the receptors. The presence and/or amount of the complexes indicate the presence and/or amount of the analyte in the sample.
Type:
Grant
Filed:
August 20, 2010
Date of Patent:
October 2, 2018
Assignee:
Siemens Healthcare Diagnostics Inc.
Inventors:
Sandra A. Lewisch, Lynn M. Schiavoni, William D. Bedzyk
Abstract: The present invention relates to an in vitro method for the detection of Procalcitonin or a fragment thereof of at least 20 amino acid residues in length in a biological sample derived from a bodily fluid obtained from a subject, comprising the steps of: (i) contacting said sample with at least two antibodies or functional fragments thereof directed against different epitopes within Procalcitonin, and (ii) qualitatively or quantitatively detecting binding of said at least two antibodies to Procalcitonin or said fragment thereof, wherein binding indicates the presence or concentration of Procalcitonin or said fragment in said sample, wherein at least one antibody or functional fragment thereof is directed against an epitope comprised in the sequence spanning amino acid residues 2 to 52 of Procalcitonin. The invention also pertains to antibodies directed against an N-terminal epitope of Procalcitonin and kits comprising antibodies directed against PCT.
Abstract: Methods for predicting a response to an erythropoietic agent in a subject include providing a biological sample from the subject, and determining an amount in the sample of at least one peptide selected from the group consisting of SEQ ID NOS: 1-17. If there is a measurable difference in the amount of the at least one peptide in the sample, when compared to a control level of the same peptide, the subject is then predicted to have a good response or a poor response to the erythropoietic agent.
Type:
Grant
Filed:
May 14, 2015
Date of Patent:
August 7, 2018
Assignee:
University of Louisville Research Foundation, Inc.
Inventors:
Michael L. Merchant, Jon B. Klein, Michael E. Brier, Adam E. Gaweda
Abstract: Methods using biomarkers, e.g., serum levels of ST2, to predict risk of developing hypertension, as well as methods for treating subjects to reduce the risk of developing hypertension and methods for selecting and/or stratifying subjects for clinical trials of treatments to reduce the risk of hypertension.
Abstract: The invention relates to dimeric proteins comprised of subunits having (i) recombinant lamprey variable lymphocyte receptor (VLR) diversity regions linked to (ii) multimerization domains. The dimeric proteins exhibit binding specificity for glycosylated antigens, and they may be used in methods of detecting or isolating glycans from a sample, and in methods of disease diagnosis, prognosis, progression monitoring, treatment, and imaging.
Type:
Grant
Filed:
November 21, 2012
Date of Patent:
July 31, 2018
Assignee:
UNIVERSITY OF MARYLAND, BALTIMORE
Inventors:
Zeev Pancer, Li Mao, Xia Hong, Mark Z. Ma
Abstract: A capturing device (20) and method for use in capturing a substance in a liquid, by feeding the liquid through a capturing device (20) including: a lateral capillary flow matrix (13) and a capturing matrix (26) in fluid communication with the lateral capillary flow matrix (13) such as to produce a lateral capillary flow in the capturing matrix having a lower velocity than that in the lateral capillary flow matrix. This produces by the Bernoulli effect, a lower pressure with respect to the two lateral flows sufficient to impart transverse oscillations to the lateral flow in the capturing matrix, such oscillations driving the liquid into the interior of the capturing matrix thereby exposing its interior, rather than merely a surface thereof, to the liquid. In the described preferred embodiments, the capturing device is a biological assay device, and each substance in the liquid to be captured in the capture zone of the capturing matrix is a biological substance.
Abstract: The present invention relates to methods and kits for predicting the risk of respiratory failure, renal failure or thrombopenia in a septic patient. More particularly, the present invention relates to a method for predicting the risk of having an organ failure selected from the group consisting of respiratory failure, renal failure and thrombopenia in a septic patient comprising a step consisting of measuring the concentration of endocan in a blood sample obtained from said septic patient.
Type:
Grant
Filed:
January 20, 2012
Date of Patent:
April 17, 2018
Assignees:
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE DROIT ET DE LA SANTE LILLE 2, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE LILLE
Abstract: A monoclonal antibody that does not show a crossreactivity with middle-molecular weight (MMW) adiponectin and specifically reacts with high-molecular weight (HMW) adiponectin alone is disclosed. The monoclonal antibody of the present invention can be produced by using HMW adiponectin as an antigen. According to the monoclonal antibody of the present invention, a convenient, high-accurate, and versatile reagent for analyzing HMW adiponectin can be provided.
Abstract: The invention provides an antibody binding specifically to Cynomolgus IgG characterized by not binding to Human IgG, and a method for the immunological determination of an immune complex (DA/ADA complex) of a drug antibody (DA) and an antibody against said drug antibody (anti-drug antibody, ADA) in a sample of a monkey species using a double antigen bridging immunoassay.
Type:
Grant
Filed:
August 5, 2014
Date of Patent:
April 3, 2018
Assignee:
HOFFMANN-LA ROCHE INC.
Inventors:
Ulrich Essig, Kay-Gunnar Stubenrauch, Rudolf Vogel, Uwe Wessels
Abstract: Methods and devices for rapid assessment of the severity of injury not due to a natural disease based upon measurement of neutrophil gelatinase-associated lipocalin (NGAL) are provided.
Abstract: The invention is based on a method for performing a biochemical analysis, especially in outer space, wherein at least one analyte in a sample is determined qualitatively and/or quantitatively by means of selective binding of an analyte-specific pair composed of a binding substance and a detection substance to the analyte and by labeling by a labeling substance, and wherein the sample, the binding substance, the detection substance and the labeling substance are mixed in a reaction vessel in one method step. It is proposed that the mixing be brought about by means of mixing bodies.
Type:
Grant
Filed:
August 16, 2013
Date of Patent:
March 20, 2018
Assignee:
Airbus DS GmbH
Inventors:
Peter Kern, Herbert Backes, Ulrich Kubler